fda update on semaglutide A big win for Wegovy: Weight loss drug first in history to gain approval for reducing heart risks FDA approves higher dose of

The secondary outcomes were improvement in the components of metabolic syndrome, lipid panel (total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein), hepatic panel (albumin, total protein, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase), and adiposity, oxidative stress, and inflammation biomarkers

Global prevalence of sexual dysfunction among diabetic patients from 2008 to 2022: Systematic review and meta-analysis

Clin endocrinology

It is a bone-deep weariness that makes the idea of physical activity, including sex, feel overwhelming rather than appealing

Some potency loss occurs